A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2 POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY